ASX - Delayed Quote AUD

Compumedics Limited (CMP.AX)

0.2600 0.0000 (0.00%)
At close: April 24 at 4:10 PM GMT+10
Loading Chart for CMP.AX
DELL
  • Previous Close 0.2600
  • Open 0.2600
  • Bid 0.2500 x 1190400
  • Ask 0.2700 x 2151600
  • Day's Range 0.2600 - 0.2600
  • 52 Week Range 0.1400 - 0.4450
  • Volume 5,227
  • Avg. Volume 17,571
  • Market Cap (intraday) 46.062M
  • Beta (5Y Monthly) 1.13
  • PE Ratio (TTM) 26.00
  • EPS (TTM) 0.0100
  • Earnings Date Feb 29, 2024
  • Forward Dividend & Yield --
  • Ex-Dividend Date Nov 23, 2004
  • 1y Target Est --

Compumedics Limited engages in the research, development, manufacturing, and distribution of medical equipment and related technologies in Australia, the Asia Pacific, the Americas, Europe, and the Middle East. It provides sleep diagnostics products, including Somfit/Somfit Pro, a wearable device for collecting patients' physiological data; Somté PSG; Okti; Grael PSG; Grael DC; Falcon HST; Somté, an investigative tool; and Somté PSG. The company also offers neurology diagnostics, such as ONsight A.V.S. for monitoring patient's home ambulatory studies; Grael 4K PSG:EEG amplifiers; Grael 4K-EEG amplifiers; Grael LT EEG System amplifiers; Neuvo 64-512 Channel LTM EEG monitoring systems; Okti, an portable EEG amplifier; and Siesta 802, a multi-functional ambulatory recording device. In addition, the company provides software products, such as Profusion Sleep software suite; Profusion EEG Software; Profusion neXus 360, a web-based patient data and lab management system that offers integrated hardware and software solutions for sleep and neurology clinics; Multi-Modal Neuroimaging Suite; Profusion neXus Laboratory Management System to optimize administrative and operational workflow needs of diagnostic and research laboratories; Profusion neXus Scheduler for planning for staff and time; and HD Digital Video, a plug-in software module to add synchronized digital video capabilities to sleep and EEG systems, as well as ECG Free, Profusion Plus, Siesta extended battery pack, summit IP, TCM5 FLEX transcutaneous monitors, and persyst software products. Further, it provides magnetoencephalography systems; brain research technologies; pharmaceutical clinical trials and research services; accessories; and consumables and supplies for diagnostic and research solutions. The company was incorporated in 1987 and is headquartered in Abbotsford, Australia. Compumedics Limited operates as a subsidiary of D & DJ Burton Holdings Pty Ltd.

www.compumedics.com.au

135

Full Time Employees

June 30

Fiscal Year Ends

Recent News: CMP.AX

Performance Overview: CMP.AX

Trailing total returns as of 4/24/2024, which may include dividends or other distributions. Benchmark is

.

YTD Return

CMP.AX
7.14%
S&P/ASX 200 [XJO]
1.21%

1-Year Return

CMP.AX
85.71%
S&P/ASX 200 [XJO]
4.93%

3-Year Return

CMP.AX
43.48%
S&P/ASX 200 [XJO]
8.81%

5-Year Return

CMP.AX
48.00%
S&P/ASX 200 [XJO]
20.38%

Compare To: CMP.AX

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: CMP.AX

Valuation Measures

Annual
As of 4/24/2024
  • Market Cap

    46.06M

  • Enterprise Value

    51.62M

  • Trailing P/E

    37.14

  • Forward P/E

    --

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    0.84

  • Price/Book (mrq)

    2.55

  • Enterprise Value/Revenue

    1.04

  • Enterprise Value/EBITDA

    14.42

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    2.46%

  • Return on Assets (ttm)

    3.54%

  • Return on Equity (ttm)

    7.07%

  • Revenue (ttm)

    50.13M

  • Net Income Avi to Common (ttm)

    1.23M

  • Diluted EPS (ttm)

    0.0100

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    3.67M

  • Total Debt/Equity (mrq)

    51.16%

  • Levered Free Cash Flow (ttm)

    -4.66M

Research Analysis: CMP.AX

Analyst Price Targets

 

Analyst Recommendations

  • Strong Buy
  • Buy
  • Hold
  • Underperform
  • Sell
 

Company Insights: CMP.AX

People Also Watch